Navigation Links
QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
Date:5/10/2010

BEDMINSTER, N.J. and SYDNEY, May 10 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

"The successful outcome of this trial reinforces QRxPharma's intellectual property that defines MoxDuo CR as a novel, controlled-release formulation for sustained pain relief. We are now one step closer to addressing the needs of chronic pain patients and entering the multi-billion dollar chronic pain market," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "QRxPharma remains on track to finalising the MoxDuo CR tablet by the end of this year and to be in a position to initiate Phase 2 trials shortly thereafter."

The Phase 1 trial, a single dose crossover design, was conducted in 14 normal healthy volunteers at one U.S. clinical research site. This study compared the rate at which key components of the CR formulation were absorbed, distributed, metabolised and eliminated by the body to the pharmacokinetic profile of Oxycontin® 20 mg (sustained release oxycodone).

Pharmacokinetic results are encouraging, and the profile is consistent with expectations for a twice-daily formulation. Data from this study will significantly aid QRxPharma and its manufacturing partner, Patheon Inc., in finalising the target release profile for the product and finalising the composition of prototype MoxDuo CR tablets.

The Company's MoxDuo® product portfolio includes both immediate and controlled release, as well as intravenous formulations. "Our goal is to provide physicians and patients with a variety of complementary Dual-Opioids for managing moderate to severe pain from hospital to home," added Holaday.


'/>"/>
SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ALTO, Calif. , Feb. 8, 2016 Lonza, ... Kodiak Sciences Inc., a biopharmaceutical company designing and developing ... today agreements for the clinical supply of Kodiak,s therapeutic ... multiple sites, including Slough (UK), Visp (CH) and Nansha ... Retinal diseases, such as age-related macular degeneration (AMD), ...
(Date:2/8/2016)... 2016  Avista Pharma Solutions ("Avista Pharma") announced today ... Financial Officer (CFO). Mr. Setzer is a finance and ... various roles within growing technology and life science companies. ... Executive Director of Finance at INC Research, a publicly ... . Previously, Mr. Setzer served as CFO of ...
(Date:2/8/2016)... Feb. 8, 2016 Vestagen Technical Textiles, Inc., ... apparel for healthcare and other demanding applications, today announced ... Officer. He replaces Dale Pfost , PhD, who ... Bold is also joining Vestagen,s Board of Directors. ... of active barrier technologies that combines fluid repellent, antimicrobial ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some dirt on ... A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay into a ... the body. , A former motivational speaker, Perry A~ has since dedicated her life ...
(Date:2/8/2016)... ... 08, 2016 , ... FileHold's document management software has been ... cloud hosted environment for FileHold software that is pay per user subscription-based and ... using the FileHold web services API. DocuSyst also advises clients on fully functioning ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published ... rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin ... a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their ... removal products. , Moles are derived from a cluster of melanin when exposed to ... wrong places and create a lifetime of embarrassment. Historically, mole removal has ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
Breaking Medicine News(10 mins):